HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

11- (2- methylpropyl)- 12,13- dihydro- 2- methyl- 8- (pyrimidin- 2- ylamino)- 4H- indazolo(5,4- a)pyrrolo(3,4- c)carbazol- 4- one

inhibits VEGF-R (TIE-2); structure in first source

Also Known As:

CEP-11981

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - Indazoles: 179
        11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Carbazoles: 32
        11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one: 1
    - Indazoles: 179
      - 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one: 1
  - 3-Ring Heterocyclic Compounds
    - Carbazoles: 32
      - 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one: 1

Experts

1.	Brown, Peter: 1 article (12/2014)
2.	Carducci, Michael: 1 article (12/2014)
3.	Hurwitz, Herbert: 1 article (12/2014)
4.	Pili, Roberto: 1 article (12/2014)

Related Diseases

1.

Neoplasms (Cancer)

12/01/2014 - "An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer."
12/01/2014 - "This phase I study evaluated the pharmacokinetics and pharmacodynamics of CEP-11981, an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, in patients with advanced, relapsed, or refractory solid tumors. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Tyrosine Kinase Inhibitors